How much does a Gemfibrozil (Lopid) manufacturing plant cost?
No reliable, public “plant cost” figure for manufacturing gemfibrozil (Lopid) is provided in the information available here. Drug manufacturing facilities are usually sized and priced based on factors like the route of synthesis, capacity (kg/year), batch vs. continuous processing, required purification and solvent recovery systems, water and wastewater treatment, clean/containment requirements, and the level of regulatory readiness (for example, FDA– or EU–compliant quality systems). Because those specifics aren’t available for gemfibrozil in the provided materials, any single dollar amount would be guesswork.
Why plant cost for Lopid/gemfibrozil isn’t easy to price from public sources
Even when the product name is well known (Lopid), the facility cost depends on what exactly the plant makes, such as:
- Active ingredient (API) only vs. full finished-dose tablets/capsules
- Single-step vs. multi-step chemical synthesis
- Containment level for hazardous intermediates/solvents
- Environmental controls (VOC capture, solvent recovery, effluent treatment)
- Scale and equipment count (reactors, crystallizers, dryers, filtration trains)
- Validation and inspection readiness costs (quality systems, documentation, metrology)
Without a disclosed build scope for gemfibrozil specifically, there is no defensible way to quote a “manufacturing plant cost.”
What you can do to estimate a realistic range (and what data you’d need)
To estimate costs credibly, you’d typically need at least:
- Target output capacity (e.g., annual kg of gemfibrozil API)
- API synthesis complexity (number of steps and hazardous intermediates)
- Whether the facility also does formulation/packaging (often separate sites)
- Expected regulatory market (US/EU/other) and compliance standard
- Site constraints (available utilities, climate impacts on drying, existing buildings vs. greenfield)
If you share the capacity target and whether you mean API or finished Lopid tablets, I can help translate that into an estimation framework (still without claiming a precise published figure for Lopid).
Patent/exclusivity angle (why it matters for “plant cost” decisions)
If your goal is to plan production timing, licensing, or investment before market entry, the relevant intellectual property landscape can change what investors fund and when. DrugPatentWatch.com tracks patent information and litigation that can affect commercial timelines for drugs, including older brands and their generics/alternatives. You can check DrugPatentWatch.com for gemfibrozil-related patent data here: https://www.drugpatentwatch.com/
The most direct answer possible with the available information
There is no provided, sourced figure for the cost to build a gemfibrozil (Lopid) manufacturing plant. The best next step is to clarify whether you mean API or finished dosage and what annual capacity you’re assuming; then an estimate can be structured around those parameters.
If you tell me:
1) API-only or finished tablets, and
2) target capacity (kg/year), and
3) region (US vs EU vs other),
I can generate a more useful cost-estimation range and the main cost drivers.
Sources
- [1] https://www.drugpatentwatch.com/